Business leader for the C2 Franchise and Therapeutics platform within PENTAX Americao Direct US C2 CryoBalloon™ market development and commercial strategy in close partnership with Sales leadershipo Tracking at 50%+ year-over-year growtho Responsible for C2 Franchise budgeto Responsible for defining clinical strategies to establish private payer reimbursement, product pipeline and new indication targets.o Partnering with European commercial leadership for a FY22 C2 Franchise launch, oversee product evaluations, KOL advocacy and support for regional sales channels o Other duties include global forecasting and collateral/Sales tools development oversight

Led the market development for the Cytosponge™, an innovative cell collection device for identifying the presence of Barrett’s esophagus.o Responsible for the US and UK commercialization strategy, development of the GI to PCP pathway and sales channel. o Created websites: Medtronic/cell-collection for HCPs and Cytosponge.com o Developed global logistics, sales, and pathology training plans.Responsible for new product innovation pipeline within the GI space through organic expansion of RFA and identification of new complementary technologies.o Initiated and established a business case to develop a system for the treatment of small bowel angioectasias; US addressable market opportunity of 60k procedures annually.Management of International market development activities to drive global RFA adoption and utilization.Led the development and commercial launch of the Barrx™ Channel RFA Endoscopic Catheter – a novel “through the scope” RFA catheter for the treatment of Barrett’s esophagus.o First year Channel Catheter sales revenue exceeded target goals by 43% - represented more than 25% of total catheter business.Managed capital and service plan programs.o Revitalized and spearheaded a new service plan program that grew revenue more than 125% two years consecutively.Launched the Barrx™ Ultra Long Focal Catheter, designed to facilitate large surface area tissue ablation.

Led the product development and European product launch of the WoundWand® Debridement Device for surgical debridement of acute and chronic wounds representing more than $500 million in potential revenue.Managed commercial launch and post market evaluations in the UK and Germany.Developed marketing collateral and competitive selling tools; led field-training efforts in UK and Germany.Supervised marketing studies and pre-clinical evaluations for European regulatory approval.Established key relationships with wound care professionals throughout the USA, UK and Germany.Coordinated several KOL meetings and product development reviews.Conducted market research for the market opportunity assessment of Coblation® technology to inpatient surgical debridement; research analyzed market opportunity, positioning, and competition.

Invented and directed development of the concept and application of Coblation technology for wound care. This effort led to the formation of ArthroCare's Wound Management Business Unit.Authored ArthroCare's intellectual property for Wound Management Venture Business Unit, which resulted in eleven patent applications.Drove the development of key relationships with wound care professionals to generate a market for the application of Coblation in wound debridement and healing.Spearheaded the development and implementation of a wound healing clinical evaluation: Prospective Case Series of TOPAZ® MicroDebrider for the Treatment of Diabetic Foot Ulcers.Successful study results propelled wound healing value proposition and intellectual property.Directed all pre-clinical research for each ArthroCare business unit; established and documented supporting mechanisms of action and effectiveness for ArthroCare products.Managed and provided guidance to direct reports and external physician consultants.Supported regulatory filings by planning, executing, and writing reports of pre-clinical studies.

Responsible for the design, development, and implementation of scientific research projects.Developed and implemented thermal quantification analyses program for ENT product line studies. Managed pre-clinical activities supporting marketing and competitive product analysis programs.Supported regulatory filings by planning, executing, and writing reports of pre-clinical studies including 510(k) Clearance for the Laryngeal product line, the Cavity® SpineWand, and numerous orthopedic devices.Managed new product Tier 1 post-market evaluations for each business unit.

Designed and launched the EVac T&A™, an ENT device for tonsillectomy and adenoidectomy procedures. Spearheaded a cost reduction program for ArthroCare's number one selling product that led to reducing material cost of goods by 10% and resulting in annual savings of over $5 million.

Designed and launched the RazorVac®, a low profile, aggressive tissue ablation device for small joints. Directed two Stanford University graduate interns.Conducted convection and fluid flow analysis using FloWorks™ that led to the launch of the Titan® and DiamondVac®, arthroscopic knee and shoulder devices designed to compete with mechanical shavers.

Conceived and developed ArthroCare's PORT™ technology, an innovative method of increasing current and thermal fluxes in ArthroCare's wet and dry field devices. Managed three cross-functional project teams which resulted in the launch of the following products:TurboVac® - ArthroCare's #1 selling product line, used to perform subacromial decompressions and in ACL reconstructions. The TurboVac product line accounts for over $50 million in sales worldwide FY2010.CAPSure® - A coagulation device, used to address ligament and tendon coagulation needs.DisCoblator™ - Used for the removal of disc tissue in microdiscectomy lumbar spine procedures.

Conducted research to develop the ability to coagulate collagen tissue to defined tissue depths. Launched the CAPS™ and CAPS-X™, ArthroCare's first products released for thermal coagulation.Designed and launched the SABER™ for cutting retinaculum tissue in lateral release procedures.